AI
I had been wondering about the enrollment completion and the date on the estimated primary completion date on the clinical trial site. (see previous post).
The August 2024 OTLK presentation has a revised time line:
See: https://ir.outlooktherapeutics.com/events-and-presentations/presentations
which matches better with the current status (Active recruiting) of Norse 8. The topline data is now expected in Q4 2024 and the submittal to the FDA will not be done this year; it is now planned for Q1 2025. That makes more sense. Approval in 2025 is realistic. And in the meantime, European sales will start Q1 2025 with Germany and the UK.
Bullish OTLK. Best of luck with your investments!
Recent OTLK News
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
